Latest News Archive

Please select Category, Year, and then Month to display items

Department of Nuclear Medicine reports successful treatment of patient with advanced stage prostate cancer

30 August 2022 | Story André Damons | Photo André Damons

UFS Nuclear Medicine — The team of doctors in the Department of Nuclear Medicine behind the success story are, from the left (standing): Dr Osayande Evbuomwan, nuclear medicine specialist and Senior Lecturer; Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS; and Dr Walter Endres, nuclear medicine registrar. In front is Dr Tebatso Tebeila, nuclear medicine registrar.

The University of the Free State (UFS) Department of Nuclear Medicine is proud to announce the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy. This was initially a case of advanced stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options.

This is a proud and happy moment for the department and the UFS, which started this treatment just over a year ago. The university and the Free State province are now joining other South African medical universities, such as the University of Pretoria, and other provinces in using this method to treat MCRPC patients. Lutetium 177 PSMA (Lu-177 PSMA) therapy is used on MCRPC patients who are not eligible for chemotherapy or have failed first- or second-line chemotherapy.

Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the department is proud to be able to offer this treatment option to some of these patients. “It is a big win for the Free State and our oncology patients to be able to offer these expert services.” The UFS and Universitas Academic Hospital have now been able to join up with other academic institutions and hospitals in other provinces to offer these services. So far, three patients have been offered this therapeutic option, with the third patient currently undergoing his treatment.

Funds and equipment for proper treatment selection are needed

The expertise is no longer an issue for the UFS, as Dr Osayande Evbuomwan, nuclear medicine specialist and consultant, was trained and exposed to this therapy at the University of the Witwatersrand during his training as a nuclear medicine resident. Current registrars in the Department of Nuclear Medicine at the UFS are also being trained in the application of this treatment modality. However, proper patient selection is key in the management of these cases with Lu 177 PSMA. Without a PET/CT camera, it is challenging to appropriately select the patients who are most likely to respond to this therapy. This is an example of how PET/CT is crucial in the management and monitoring of oncology patients.

Both Drs Engelbrecht and Evbuomwan hope that the training of more registrars will increase their department’s capacity to treat more patients. They also hope that funds will be made available to acquire a much-needed PET/CT camera, which will greatly assist them in identifying the correct patients in need of this treatment.

With the permission of the patient, the images above show the dramatic treatment response following Lu-177 PSMA therapy. The images on the left show widespread bone disease from the prostate cancer, including the skull. The images on the right show the dramatic response after completing four cycles of Lu 177 PSMA, with the normal excretion of the radiotracer seen in the liver, kidneys, and bladder.

Treatment puts the department, UFS, and hospital on the map

According to Dr Evbuomwan, the ability to administer this treatment puts the department, the UFS, and the hospital on the map, alongside other top universities within and outside the country. Says he: “It also creates an avenue for us to gather data for training, research purposes, and publications. We are now able to offer a promising, safe, and highly efficacious therapy for patients with MCRPC in the Free State. Some of these patients will no longer have to travel to other provinces to receive this treatment.”

“We are also well aware that not every patient will respond this way; however, proper patient selection is key in identifying responders – an area that is still being researched. We also do not know how long these patients will have their disease under control after the treatment. Nuclear medicine’s greatest cancer therapy success story is the treatment of well-differentiated thyroid cancer with radioactive iodine.”

“After treatment, most of these patients remain cancer-free for a very long period of time, if not for life. With continuing research in the field of MCRPC radioligand therapy, we aim to improve the treatment modality, hopefully getting it to the success level of thyroid cancer therapy.”

News Archive

International Year of Crystallography attracts science experts from across the globe

2014-10-13

Video: Discover what Chrystallopgraphy can do for you
Video: Celebrating Crystallography: An Animated Adventure

Summit programme

The third world summit in the International Year of Crystallography (in Africa) will be hosted by the UFS Department of Chemistry here on the Bloemfontein Campus. Prof André Roodt, Head of the Department of Chemistry, was elected as the President of the European Crystallographic Association in 2012. Earlier this year he unveiled the Max von Laue 'Plaque' in Posnan, Poland.

The Pan-African Meeting of the International Year of Crystallography consists of a congress and summit. The details are as follows:

Congress
12–15 October 2014
CR Swart Senate Hall, UFS Bloemfontein Campus

Summit
15–17 October 2014
CR Swart Senate Hall, UFS Bloemfontein Campus
Summit opening: Wednesday 15 October 2014 at 14:00 in the CR Swart Senate Hall

This event will be opened and attended by:
•   the UFS Rector and Vice-Rector – Profs Jonathan Jansen and Corli Witthuhn;
•   the acting Director-General of the Department of Science and Technology – Dr Thomas Auf der Heyde;
•   the acting CEO of the National Research Foundation – Dr Gansen Pillay;
•   the UNESCO Vice-Director for Science Extension – Dr Jean-Paul Ngome-Abiaga (Paris, France);
•   the representative of the Executive Committee for the International Union of Crystallography (IUCr) – Prof Santiago Garcia-Granda (Oviedo: Spain);
•   the marketing director of the IUCr – Prof Michele Zema (Pavia, Italy);
•   the President of the European Crystallographic Association (ECA) – Prof André Roodt, who will officially open the summit on Wednesday 15 October 2014 from 14:00–15:30.

Presenters from across Africa and Europe will deliver papers at this event which will be attended by more than 100 delegates from twenty-plus countries, including Spain, France, Italy, Croatia, Germany, Russia and India.

Numerous crystallographic research areas will be covered. This includes:
•   powder diffraction,
•   small molecule crystallography,
•   biological crystallography,
•   industrial crystallography,
•   surface crystallography,
as well as techniques such as
•   electron microscopy and
•   synchrotron work.

“At this event we hope to establish an African Crystallographic Association,” said Prof Roodt.

The United Nations declared 2014 as the International Year of Crystallography. It was recently officially opened at the UNESCO headquarters in Paris, France, by the Secretary General of the UN, Ban Ki-moon.

The International Year of Crystallography celebrates the centennial of the work of Max von Laue and the father and son, William Henry and William Laurence Bragg. More generally, it celebrates what crystallography can do for humanity – which proves to be a significant amount.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept